Acadia outlines 2026 revenue target up to $1.28B while advancing DAYBUE STIX and NUPLAZID growth
Source: SeekingAlpha
2026-02-26 01:58:25 ET
More on Acadia Pharma
- ACADIA Pharmaceuticals Inc. (ACAD) Q4 2025 Earnings Call Transcript
- ACADIA Pharmaceuticals Inc. 2025 Q4 - Results - Earnings Call Presentation
- 44th Annual J.P. Morgan Healthcare Conference
- Seeking Alpha’s Quant Rating on Acadia Pharma
- Historical earnings data for Acadia Pharma
Read the full article on Seeking Alpha
For further details see:
Acadia outlines 2026 revenue target up to $1.28B while advancing DAYBUE STIX and NUPLAZID growth
ACADIA Pharmaceuticals Inc.
NASDAQ: ACAD
ACAD Trading
2.8% G/L:
$22.715 Last:
372,473 Volume:
$22.52 Open:
ACAD Latest News
March 09, 2026 09:54:00 am
Neuropsychiatric Innovation Draws Big Pharma Interest and Fresh Investment
March 03, 2026 04:05:00 pm
Acadia Pharmaceuticals Appoints Jonathan M. Poole to its Board of Directors
ACAD Stock Data
$3,864,112,700
124,348,635
0.05%
128
N/A
Biotechnology & Life Sciences
Healthcare
US
San Diego
